

Remicade (Infliximab) Patient Referral and Prescription Sheet

Patient Information							
Patient Name:			Date:	Date:			
DOB:			Height:	Height: 🛛 inche		ches 🛛 cm	
Allergies:			Weight:	Weight:		lbs 🛛 kg	
Primary Diagnosis							
Diagnosis ICD-10 Diagnosis					ICD-10		
□ Crohn's Disease of small intestine without complications K50.00 □ Crol			Crohn's Disease of large intestine without complications			K50.10	
□ Crohn's Disease, unspecified without complications K50.90 □ Ulcerati			ve Chronic pancolitis without complications K51.00				
□ Plaque Psoriasis L40.0 □ Psoriati			priatic Psoriasis L40.				
□ Rheumatoid arthritis, unspecified M06.9 □ Ankylo			losing Spondylitis			M45.9	
Ulcerative Colitis, unspecified without complications	D Other						
Medication Order							
Remicade Renflexis Avsola Infl	iximab	Inflectra	Zymfentra	🛛 Refi	lls x one year		
Dosing: from date of Initiation: Administermg/kg IV over at least two hours at weeks 0, 2 and 6 per protocol signature unless Maintenance: Administermg/kg IV overminutes everyweeks indicated below Round to the nearest 100mg vial size OR exact dose of:mg maintenance: Administermg/kg IV overminutes everyweeks 120mg SC every 2 weeks maintenance: Administration of medication. Initiate plan of treatment for ongoing nursing services. Insert or access and maintain access device as indicated in Ancillary Orders. Remove peripheral IV or access from implanted VAD when infusion is completed. Pre-medications: IV Flush Orders: Diphenhydramine: 25mg PO 30 min pre-infusion Peripheral: NS 1-3 mL before/after use Accetaminophen: 650mg PO 30 min pre-infusion Implanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Iso draw. Heparin (100 unit/mL) 3 to 5 mL final flush CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw							
			10 units/mL) 3 to 5 mL final flush				
Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr							
Therapy Specific Documentation			Other Required Documentation				
ase include the following lab results Patient Demographics – include insurance information. We wauthorization unless the insurance dictates otherwise. I H & P OR progress note(s) I H & P OR progress note(s) Medication List- Please list past and present DMARDS/biolog with dates of discontinue, if applicable I Hepatitis B Surface Antigen I Hepatitis B Core Antibody Total (not Core IgM) QuantiFERON-TB Gold 							
Provider Information							
Provider Name:			Provider Phone:				
Provider NPI:			Provider Fax:				
Provider Address:							

I authorize KabaFusion and its representatives to act as an agent and initiate and execute any insurance prior authorization process for this prescription and any future refills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: _

Date: ____

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.